Table 3.
Application of different cell death regulators in TNBC
| Cell death pathway involved | Drugs | Mechanism | Reference |
|---|---|---|---|
| Apoptosis | ABT-737 | ABT-737 attaches to Bcl-2/Bcl-xL/Bcl-w, stopping them from interacting with Bax and Bak, which in turn lifts the suppression of apoptosis | [395] |
| LCL161 | LCL161 blocks IAPs, lifting their inhibition of apoptosis, and alters the tumor microenvironment by drawing macrophages to the tumor location | [396] | |
| APR-246 | When p53 is activated, it increases the levels of pro-apoptotic proteins, such as Bax and PUMA, and decreases the levels of anti-apoptotic proteins such as Bcl-2 and Bcl-xL | [397, 398] | |
| Pembrolizumab | Blocking the PD-1/PD-L1 immune checkpoint activates CTLs and triggers cancer cell apoptosis via T cell-mediated cytotoxicity | [376, 399] | |
| Epothilone B | Induction of cancer cell apoptosis via the PI3K/AKT/mTOR signaling pathway enhances the apoptotic effects of ABT-737 | [286] | |
| Pyroptosis | Cisplatin | Activation of the MEG3/NLRP3/caspase-1/GSDMD pathway in TNBC induces pyroptosis to exert anti-tumor effects | [383] |
| AZU1 | Regulation of the pNF-κB/NLRP3/caspase-1/GSDMD axis in TNBC promotes pyroptosis | [400] | |
| MCC950 | By binding to the NACHT domain of NLRP3, its oligomerization and activation are prevented, which inhibits its function and makes TNBC cells more sensitive to PTX | [279] | |
| CY-09 | Inhibiting the Walker B motif of NLRP3 reduces its activity, which in turn suppresses IL-1β/EMT/Wnt/β-catenin signaling and makes TNBC cells more sensitive to GDC-0941 | [401] | |
| OLT1177 | Inhibition of NLRP3-induced IL-1β prevents the progression of TNBC | [402] | |
| Autophgy | CQ | Preventing the fusion of autophagosomes with lysosomes results in the buildup of autophagosomes inside the cell, which encourages the death of tumor cells | [288, 289] |
| Toosendanin | Raising lysosomal pH inhibits autolysosome maturation, thereby suppressing late-stage autophagy in TNBC cells | [403] | |
| circEGFR | The translocation of annexin A2 (ANXA2) to the plasma membrane in TNBC cells facilitates the dissociation of the transcription factor TFEB from the ANXA2-TFEB complex, subsequently promoting autophagy. Concurrently, circEGFR acts as a competing endogenous RNA (ceRNA) by directly binding to miR-224-5p, thereby inhibiting its expression and mitigating the suppression of autophagy mediated by the miR-224-5p/ATG13/ULK1 axis | [404] | |
| UBC12 | Enhancing TRIM25 sumoylation boosts its interaction with TFEB, which promotes the transcription and activation of genes related to autophagy | [405] | |
| Necroptosis | ZBP1 | When glucose is deprived, mtDNA is released into the cytoplasm, where it attaches to ZBP1, triggering MLKL activation in a manner dependent on Bcl-2 family proteins and NOXA | [406] |
| Curcuma longa | Enhanced expression of TRAIL under acidic conditions induces necroptotic apoptosis in a RIPK1- and RIPK3-dependent manner | [407] | |
| Ferroptosis | Erastin | Blocking System Xc- on the cell membrane lowers cystine absorption, which results in reduced GSH production inside the cell and weakened antioxidant defenses, thus encouraging lipid peroxidation and ferroptosis | [218, 219] |
| Sulfasalazine | Blocking VDAC in mitochondria impairs their function, leading to the release of iron ions and heightened oxidative stress | [408, 409] | |
| RSL3 | Inhibition of GPX4 activity elevates intracellular lipid peroxidation levels, thereby promoting ferroptosis | [292, 293] | |
| Liproxstatin-1 | In TNBC cells, the activation of cPLA2α leads to the activation of ACSL4, which facilitates the attachment of PUFAs to coenzyme A, thereby raising lipid peroxidation levels and inducing ferroptosis | [410] | |
| Eupaformosanin | Ubiquitination of mutant p53 induces apoptosis and ferroptosis in TNBC cells | [320] |